Feasibility of home administration of nebulised interferon beta-1a (SNG001) for COVID-19: a remote study
Feasibility of home administration of nebulised interferon beta-1a (SNG001) for COVID-19: a remote study
Background: effective therapeutics given early to high-risk ambulatory patients with coronavirus disease-2019 (COVID-19) could improve outcomes and reduce overall healthcare burden. However, conducting site visits in non-hospitalised patients, who should remain isolated, is problematic.
Aim: to evaluate: feasibility of a purely remote (virtual) study in non-hospitalised patients with COVID-19; and efficacy and safety of nebulised recombinant interferon-β1a (SNG001) in this setting.
Design & setting: randomised, double-blind, parallel-group, conducted remotely.
Method: eligible patients aged ≥65 years (or ≥50 years with risk factors) with COVID-19 and not requiring hospital admission were recruited remotely. They were randomised to SNG001 or placebo once-daily via nebuliser for 14 days. The main outcomes were assessments of feasibility and safety, all conducted remotely.
Results: of 114 patients treated, 111 (97.4%) completed 28 days of follow-up. Overall compliance to study medication was high, with ≥13 doses taken by 89.7% and 92.9% of treated patients in the placebo and SNG001 groups, respectively. Over the course of the study only two patients were hospitalised, both in the placebo group; otherwise there were no notable differences between treatments for the efficacy parameters. No patients withdrew due to an adverse event, and a similar proportion of patients experienced on-treatment adverse events in the two treatment groups (64.3% and 67.2% with SNG001 and placebo, respectively); most were mild/moderate and not treatment-related.
Conclusion: this study demonstrated that it is feasible to conduct a purely virtual study in community-based patients with COVID-19, when the study included detailed daily assessments and with medication administered via nebuliser.
Clinicaltrialsgov: NCT04385095.
Francis, Nick
9b610883-605c-4fee-871d-defaa86ccf8e
Monk, Phillip D
44d7fae5-8426-4210-a296-358c18958088
Nuttall, Jacqueline
154aec0a-05f2-4379-918e-9c36767fdc4c
Oliver, Thomas
26d485ae-9f07-4a9e-96dc-c63f84246223
Simpson, Catherine
60c008cf-9ba0-4c41-815c-ad66a04aaed2
Brookes, Jody L.
fcaf3378-ab49-44ec-8dbb-e35410401465
Tear, Victoria J.
2db78fa3-fa9d-4172-ae25-e1cc8247dcc4
Thompson, Angela G.
0706148f-1224-4802-a4b1-9943b89fd750
Batten, Toby N.
5a982c3a-58ed-4ba5-baac-81a5928b2ceb
Mankowski, Marcin
8f4944d6-ed36-4d04-831c-d268c5e02b52
Wilkinson, Thomas
8c55ebbb-e547-445c-95a1-c8bed02dd652
December 2023
Francis, Nick
9b610883-605c-4fee-871d-defaa86ccf8e
Monk, Phillip D
44d7fae5-8426-4210-a296-358c18958088
Nuttall, Jacqueline
154aec0a-05f2-4379-918e-9c36767fdc4c
Oliver, Thomas
26d485ae-9f07-4a9e-96dc-c63f84246223
Simpson, Catherine
60c008cf-9ba0-4c41-815c-ad66a04aaed2
Brookes, Jody L.
fcaf3378-ab49-44ec-8dbb-e35410401465
Tear, Victoria J.
2db78fa3-fa9d-4172-ae25-e1cc8247dcc4
Thompson, Angela G.
0706148f-1224-4802-a4b1-9943b89fd750
Batten, Toby N.
5a982c3a-58ed-4ba5-baac-81a5928b2ceb
Mankowski, Marcin
8f4944d6-ed36-4d04-831c-d268c5e02b52
Wilkinson, Thomas
8c55ebbb-e547-445c-95a1-c8bed02dd652
Francis, Nick, Monk, Phillip D, Nuttall, Jacqueline, Oliver, Thomas, Simpson, Catherine, Brookes, Jody L., Tear, Victoria J., Thompson, Angela G., Batten, Toby N., Mankowski, Marcin and Wilkinson, Thomas
(2023)
Feasibility of home administration of nebulised interferon beta-1a (SNG001) for COVID-19: a remote study.
BJGP Open, 7 (4).
(doi:10.3399/BJGPO.2023.0089).
Abstract
Background: effective therapeutics given early to high-risk ambulatory patients with coronavirus disease-2019 (COVID-19) could improve outcomes and reduce overall healthcare burden. However, conducting site visits in non-hospitalised patients, who should remain isolated, is problematic.
Aim: to evaluate: feasibility of a purely remote (virtual) study in non-hospitalised patients with COVID-19; and efficacy and safety of nebulised recombinant interferon-β1a (SNG001) in this setting.
Design & setting: randomised, double-blind, parallel-group, conducted remotely.
Method: eligible patients aged ≥65 years (or ≥50 years with risk factors) with COVID-19 and not requiring hospital admission were recruited remotely. They were randomised to SNG001 or placebo once-daily via nebuliser for 14 days. The main outcomes were assessments of feasibility and safety, all conducted remotely.
Results: of 114 patients treated, 111 (97.4%) completed 28 days of follow-up. Overall compliance to study medication was high, with ≥13 doses taken by 89.7% and 92.9% of treated patients in the placebo and SNG001 groups, respectively. Over the course of the study only two patients were hospitalised, both in the placebo group; otherwise there were no notable differences between treatments for the efficacy parameters. No patients withdrew due to an adverse event, and a similar proportion of patients experienced on-treatment adverse events in the two treatment groups (64.3% and 67.2% with SNG001 and placebo, respectively); most were mild/moderate and not treatment-related.
Conclusion: this study demonstrated that it is feasible to conduct a purely virtual study in community-based patients with COVID-19, when the study included detailed daily assessments and with medication administered via nebuliser.
Clinicaltrialsgov: NCT04385095.
Text
BJGPO.2023.0089.full
- Accepted Manuscript
More information
Accepted/In Press date: 11 August 2023
e-pub ahead of print date: 5 September 2023
Published date: December 2023
Additional Information:
Copyright © 2023, The Authors.
Identifiers
Local EPrints ID: 482080
URI: http://eprints.soton.ac.uk/id/eprint/482080
PURE UUID: 72da9e36-3aad-4e23-a62c-8dcc5cb2b8dd
Catalogue record
Date deposited: 19 Sep 2023 16:31
Last modified: 18 Apr 2024 01:57
Export record
Altmetrics
Contributors
Author:
Phillip D Monk
Author:
Jacqueline Nuttall
Author:
Thomas Oliver
Author:
Catherine Simpson
Author:
Jody L. Brookes
Author:
Victoria J. Tear
Author:
Angela G. Thompson
Author:
Toby N. Batten
Author:
Marcin Mankowski
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics